Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, June 28, 2024 /PRNewswire/ — Sirnaomics Ltd. (the “Company”, together with its subsidiaries, the “Group” or “Sirnaomics”; stock code: 2257), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi…